Predicting response to neoadjuvant therapy in esophageal cancer with p53 genotyping: a fortune-teller's crystal ball or a viable prognostic tool?

J Thorac Cardiovasc Surg. 2014 Nov;148(5):2286-7. doi: 10.1016/j.jtcvs.2014.09.036. Epub 2014 Sep 18.

Author

Katie S Nason¹

Affiliation

¹ Division of Thoracic and Foregut Surgery, Department of Cardiothoracic Surgery, University of Pittsburgh, Pittsburgh, Pa. Electronic address: nasonks@upmc.edu.

PMID: 25444198
DOI: 10.1016/j.jtcvs.2014.09.036

No abstract available

Publication types

Editorial
Comment

MeSH terms

Adenocarcinoma / drug therapy*
Adenocarcinoma / genetics*
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Biomarkers, Tumor / genetics*
Carcinoma, Squamous Cell / drug therapy*
Carcinoma, Squamous Cell / genetics*
Esophageal Neoplasms / drug therapy*
Esophageal Neoplasms / genetics*
Female
Humans
Male
Mutation*
Neoadjuvant Therapy*
Tumor Suppressor Protein p53 / genetics*

Substances

Biomarkers, Tumor
TP53 protein, human
Tumor Suppressor Protein p53

Supplementary concepts

Adenocarcinoma Of Esophagus